Title:

Will the patient-centric approach of Value-based Healthcare drive innovation in HTA?

Introduction:

HTA has a pivotal role in addressing healthcare challenges: improving patient outcomes, achieving value for healthcare spending, addressing budgetary restraints and maintaining healthcare sustainability (1). Having the shared, overarching goal of achieving high value for patients has been proposed as a means to address these challenges (2). This patient-centric approach is commonly defined as Value-Based Healthcare (VBHC), focussing on outcomes that matter to patients relative to the costs of achieving those outcomes. Two global initiatives are creating systems to measure and report patient outcomes in a standardized way to support a range of goals related to VBHC and learning health systems – International Consortium for Health Outcomes Measurement (ICHOM) and Core Outcome Measures in Effectiveness Trials (COMET). This panel will present these initiatives and discuss how patient-outcome centred approaches can reshape how we define, measure and assess value. The panel will consider what this means for driving innovation in HTA.

Structure of the session:

The increased global focus on patient outcomes raises new questions for the HTA community and its stakeholders (patients, clinicians, hospitals, payers, industry). E.g. do we need new HTA methodologies to fully capture and realise the value of new healthcare interventions to patients? What does this mean for how evidence is generated? What does this mean for data collection frameworks and the importance of ‘real world’ evidence? How do we reward innovation and support the development of learning health systems? Should HTA have an active role in informing outcomes-based reimbursement? These and other considerations will be examined in this panel.

Panel members will speak to European, Canadian and Australian experiences, including ICHOM, COMET, HTA agency, and patient and industry perspectives. The moderator will highlight existing commonalities and identify opportunities for collaboration, and push the panellists to consider whether there are other issues that need to be more fully considered. The panel will include individuals who are well suited to present their organization’s perspectives and experiences with a patient-centric approach to defining value. After short presentations (10 minutes) from each panelist, the remainder of the time will be dedicated to audience discussion/Q&A, which will be carefully managed by the moderator.
Panel/Workshop outcome and objectives:

The objective of this panel is to raise awareness of VBHC, ICHOM and COMET and through discussion with the audience consider what this means for the HTA community and its key stakeholders. It will provide an opportunity to discuss the practical challenges and solutions required to change current HTA approaches and influence healthcare sustainability and learning.

The outcomes from this panel include the potential for greater collaboration amongst the HTA community, ICHOM and COMET and for review of HTA processes to be more outcome focussed. As a result, this panel should be of interest to all HTA stakeholders - HTA agencies, methodologists, decision makers, clinicians, patients and the medical device and pharmaceutical industry.

References:


Panellists:

Dr Thomas Kelley (ICHOM)

Dr Paula Williamson (COMET);

Dr Liesl Strachan (Medtronic/Industry);

Mark Skinner (Patient/lawyer) - USA;

Dr Tammy Clifford (CADTH);

Moderator: Dr Karen Facey